Arvinas (ARVN) Depreciation & Amortization (CF) (2017 - 2026)
Arvinas (ARVN) posted quarterly Depreciation & Amortization (CF) of $700000.0 for Q1 2026, little changed year-over-year from $700000.0 in Q1 2025, and little changed quarter-over-quarter from $700000.0 in Q4 2025.
Analysis
Arvinas (ARVN) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Arvinas' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $700000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) changed 0.0% year-over-year to $700000.0; the TTM figure through Mar 2026 stood at $3.0 million (down 26.83% YoY), while the FY2025 annual figure was $3.0 million, down 34.78% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $700000.0, roughly flat from $700000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $1.7 million in Q4 2022, with the low at $700000.0 in Q1 2025.
- The 5-year median for Depreciation & Amortization (CF) is $1.2 million (2023), against an average of $1.1 million.
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) surged 36.36% in 2022, then sank 41.67% in 2025.
- Arvinas' Depreciation & Amortization (CF) stood at $1.7 million in 2022, then dropped by 29.41% to $1.2 million in 2023, then fell by 8.33% to $1.1 million in 2024, then sank by 36.36% to $700000.0 in 2025, then changed by 0.0% to $700000.0 in 2026.
- Business Quant data shows ARVN's Depreciation & Amortization (CF) at $700000.0 in Q1 2026, $700000.0 in Q4 2025, and $800000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Arvinas | 609.77 Mn | 41.87 Mn | - | 700,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 700,000.00 |
| Mar 31, 2026 | 700,000.00 |
| Dec 31, 2025 | 700,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Mar 31, 2025 | 700,000.00 |
| Dec 31, 2024 | 1.10 Mn |
| Sep 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.20 Mn |
| Dec 31, 2023 | 1.20 Mn |
| Sep 30, 2023 | 1.20 Mn |
| Jun 30, 2023 | 1.20 Mn |
| Mar 31, 2023 | 1.20 Mn |
| Dec 31, 2022 | 1.70 Mn |
| Sep 30, 2022 | 1.60 Mn |
| Jun 30, 2022 | 1.50 Mn |
| Mar 31, 2022 | 1.50 Mn |
| Dec 31, 2021 | 1.30 Mn |
| Sep 30, 2021 | 1.20 Mn |